摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[6-Chloro-4-(3-piperazin-1-ylphenyl)quinazolin-2-yl]-2,3-dimethylguanidine

中文名称
——
中文别名
——
英文名称
1-[6-Chloro-4-(3-piperazin-1-ylphenyl)quinazolin-2-yl]-2,3-dimethylguanidine
英文别名
1-[6-chloro-4-(3-piperazin-1-ylphenyl)quinazolin-2-yl]-2,3-dimethylguanidine
1-[6-Chloro-4-(3-piperazin-1-ylphenyl)quinazolin-2-yl]-2,3-dimethylguanidine化学式
CAS
——
化学式
C21H24ClN7
mdl
——
分子量
409.9
InChiKey
SRJIKMDXTTYGCD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    77.5
  • 氢给体数:
    3
  • 氢受体数:
    5

文献信息

  • COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
    申请人:Ardelyx, Inc.
    公开号:US20140107074A1
    公开(公告)日:2014-04-17
    The present disclosure is directed to compounds of the structure (X): wherein: n is 2 or 3; NHE has the structure wherein: R 1 is H or —SO 2 —NR 7 R 8 —; R 2 is selected from H, —NR 7 (CO)R 8 , —SO 2 —NR 7 R 8 — and —NR 7 R 8 ; R 3 is hydrogen; R 7 is hydrogen; R 8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(═O)—, —NHC(═O)NH— and —NHSO 2 —; and Y is selected from the group consisting of a bond, optionally substituted C 1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH 2 ) 1-6 O(CH 2 ) 1-6 —, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.
    本公开涉及结构为(X)的化合物,其中:n为2或3;NHE具有以下结构:其中:R1为H或—SO2—NR7R8—;R2选自H,—NR7(CO)R8,—SO2—NR7R8—和—NR7R8;R3为氢;R7为氢;R8为与L连接的键;L为聚乙二醇连接剂;Core具有以下结构:其中:X选自以下组中的一种:键,—O—,—NH—,NHC(═O)—,—NHC(═O)NH—和—NHSO2—;Y选自以下组中的一种:键,可选取代的C1-6烷基,可选取代的苯,吡啶基,聚乙二醇连接剂和—(CH2)1-6O( )1-6—,以及使用这种化合物治疗肠易激综合征、慢性肾脏病和终末期肾脏病的方法。
  • COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER
    申请人:Ardelyx, Inc.
    公开号:US20150190389A1
    公开(公告)日:2015-07-09
    The present disclosure is directed to compounds of the structure (X): CoreL-NHE) n (X) wherein: n is 2 or 3; NHE has the structure wherein: R 1 is H or —SO 2 —NR 7 R 8 —; R 2 is selected from H, —NR 7 (CO)R 8 , —SO 2 —NR 7 R 8 — and —NR 7 R 8 ; R 3 is hydrogen; R 7 is hydrogen; R 8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(═O)—, —NHC(═O)NH— and —NHSO 2 —; and Y is selected from the group consisting of a bond, optionally substituted C 1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH 2 ) 1-6 O(CH 2 ) 1-6 —, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.
    本公开涉及结构为(X):CoreL-NHE)n(X)的化合物,其中:n为2或3;NHE具有以下结构:其中:R1为H或—SO2—NR7R8—;R2选自H,—NR7(CO)R8,—SO2—NR7R8—和—NR7R8;R3为氢;R7为氢;R8为连接到L的键;L为多聚乙二醇连接剂;Core具有以下结构:其中:X选自由键,—O—,—NH—,NHC(═O)—,—NHC(═O)NH—和—NHSO2—;Y选自键,可选择性地取代的C1-6烷基,可选择性地取代的苯,吡啶基,聚乙二醇连接剂和—(CH2)1-6O( )1-6—,以及使用这种化合物治疗肠易激综合征、慢性肾脏病和终末期肾脏疾病的方法。
  • NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
    申请人:ARDELYX, INC
    公开号:US20160067242A1
    公开(公告)日:2016-03-10
    Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
  • US8969377B2
    申请人:——
    公开号:US8969377B2
    公开(公告)日:2015-03-03
  • US9006281B2
    申请人:——
    公开号:US9006281B2
    公开(公告)日:2015-04-14
查看更多